Real-world outcomes of mepolizumab for the treatment of severe eosinophilic asthma in Canada: an observational study

Mepolizumab, the first widely available anti-interleukin 5 biologic, targets eosinophilic inflammation and has been shown in clinical trials to reduce exacerbations, oral corticosteroid dependence, and healthc...

Source: Allergy, Asthma and Clinical Immunology - February 4, 2024 Category: Allergy & Immunology Authors: Kenneth R. Chapman, Kathryn Cogger, Erin Arthurs, Callahan LaForty, Shane Golden, Bradley Millson, Koyo Usuba and Christopher Licskai Tags: Research Source Type: research